Entropy Neurodynamics

Entropy Neurodynamics Depreciation & Amortization

The Depreciation & Amortization of Entropy Neurodynamics (ENP.AX) as of Nov 22, 2026 is 54,300.00 AUD. In the previous year, Depreciation & Amortization was 6,800.00 AUD — a change of 698.53% (higher).

Depreciation & Amortization

54,300.00AUD

YoY

698.53%

Last updated:

Depreciation & Amortization of Entropy Neurodynamics is 2025 54,300.00 AUD. Depreciation & Amortization of Entropy Neurodynamics was 2024 6,800.00 AUD. It decreases by 698.53% higher compared to the previous year.

The Entropy Neurodynamics Depreciation & Amortization history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Depreciation & Amortization
Date
Depreciation & Amortization
Jan 1, 2021
1.01 M AUD
Jan 1, 2022
1.73 M AUD
Jan 1, 2023
1.70 M AUD
Jan 1, 2024
6,800.00 AUD
Jan 1, 2025
54,300.00 AUD
The Entropy Neurodynamics Depreciation & Amortization history
YEARDepreciation & AmortizationYoY
54,300.00AUD+698.53%
6,800.00AUD-99.60%
1.70 MAUD-1.56%
1.73 MAUD+71.74%
1.01 MAUD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Entropy Neurodynamics Stock analysis

What does Entropy Neurodynamics do? Entropy Neurodynamics Ltd develops and commercializes exosomes as therapeutic agents. The company holds intellectual property related to exosome technology and offers LEAP manufacturing, LOAD API loading, and EVPS tropism technologies. Pharmaceutical and biotechnology companies purchase these proprietary technologies to enhance their own exosome-based products. The firm invests in biopharmaceutical drug development and leverages its portfolio of know-how to support partners in exosome medicine development. Exopharm Ltd. is the company's brand name, and it operates through its exosome technology portfolio. The firm's technologies solve key challenges in exosome medicine success, including manufacturing efficiency and targeted delivery. Biopharmaceutical companies are the primary buyers of these technologies, seeking to integrate exosome delivery systems into their therapeutic pipelines. The company's business model centers on licensing its exosome-related IP and know-how to pharmaceutical and biotech firms. By providing LEAP, LOAD API, and EVPS technologies, Entropy Neurodynamics enables partners to overcome technical barriers in exosome-based drug development. This approach generates revenue through technology licensing agreements with industry partners. Entropy Neurodynamics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Entropy Neurodynamics stock

Depreciation & Amortization of Entropy Neurodynamics is 54,300.00 AUD in 2025.

Depreciation & Amortization of Entropy Neurodynamics changed from 6,800.00 AUD to 54,300.00 AUD, representing a 698.53% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Depreciation & Amortization Entropy Neurodynamics since 2006 – with annual values, charts, and detailed analysis.

Depreciation & Amortization represents the allocation of the cost of tangible and intangible assets over their useful lives.

Depreciation & Amortization's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Depreciation & Amortization's Entropy Neurodynamics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Entropy Neurodynamics

All Key Metrics — Entropy Neurodynamics